- Stocks
- Pharma & Healthcare
- Jupiter Life Line Hospitals
Jupiter Life Line Hospitals share price
NSE: JLHLPharma & HealthcareMedical Care Facilities
Jupiter Life Line Hospitals at a glance
Jupiter Life Line Hospitals (NSE: JLHL) closed at ₹244.75 on 22 Oct 2026, down 0.87% on the day. With a market capitalisation of ₹1,605 Cr, it ranks 1230th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 8.3× trailing earnings, against a return on equity of 12.6% in FY26. Over the past year the share price has fallen 20.0%. Its 52-week range is ₹234.95 (15 Oct 2026) to ₹340.00 (30 Jul 2026); the last close is 28.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹411 Cr (+18.2% year on year) and net profit ₹38 Cr (−14.5%), on a consolidated basis. Promoters held 40.91% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,605 CrRank 1230 on NSE
- P/E (trailing)
- 8.3×
- Price to book
- 5.4×FY26
- EPS (TTM)
- ₹28.62to Q1 FY27
- ROE
- 12.6%FY26
- ROCE
- 13.8%FY26
- Debt to equity
- 0.33FY26
- Net profit margin
- 12.9%FY26
- Book value / share
- ₹235.50FY26
- Dividend payout
- 3.4%FY26
- 52-week high
- ₹340.0030 Jul 2026
- 52-week low
- ₹234.9515 Oct 2026
- 1-year return
- −20.0%
- RSI (14-day)
- 39
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.87% | +1.1% | −10.4% | −21.8% | −20.0% |
Jupiter Life Line Hospitals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹323 Cr | ₹321 Cr | ₹327 Cr | ₹348 Cr | ₹394 Cr | ₹365 Cr | ₹388 Cr | ₹411 Cr |
| Revenue YoY | +22.6% | +17.6% | +12.5% | +21.1% | +22.0% | +14.0% | +18.7% | +18.2% |
| Net profit | ₹52 Cr | ₹53 Cr | ₹45 Cr | ₹44 Cr | ₹57 Cr | ₹43 Cr | ₹50 Cr | ₹38 Cr |
| Net profit YoY | +52.9% | +20.2% | −0.9% | −1.6% | +11.6% | −19.1% | +12.0% | −14.5% |
| Net margin | 16.0% | 16.4% | 13.7% | 12.6% | 14.6% | 11.6% | 13.0% | 9.1% |
| EPS | ₹7.86 | ₹8.01 | ₹6.84 | ₹6.69 | ₹8.75 | ₹6.49 | ₹7.66 | ₹5.72 |
Jupiter Life Line Hospitals financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹486 Cr | ₹733 Cr | ₹893 Cr | ₹1,070 Cr | ₹1,262 Cr | — |
| Operating profit | ₹2 Cr | ₹77 Cr | ₹131 Cr | ₹195 Cr | ₹258 Cr | — |
| Net profit | −₹2 Cr | ₹51 Cr | ₹73 Cr | ₹177 Cr | ₹194 Cr | — |
| EPS (₹) | ₹0.00 | ₹10.00 | ₹14.00 | ₹29.00 | ₹29.00 | — |
| Cash from operations | ₹123 Cr | ₹137 Cr | ₹176 Cr | ₹115 Cr | ₹253 Cr | — |
| Total debt | ₹421 Cr | ₹465 Cr | ₹453 Cr | ₹0 Cr | ₹322 Cr | ₹501 Cr |
| Shareholders' equity | ₹239 Cr | ₹292 Cr | ₹366 Cr | ₹1,169 Cr | ₹1,356 Cr | ₹1,544 Cr |
Jupiter Life Line Hospitals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 40.91% | 40.91% | 40.91% | 40.91% | 40.91% | 40.91% |
| Foreign institutions | 10.03% | 9.77% | 9.06% | 8.48% | 8.48% | 9.37% |
| Domestic institutions | 15.63% | 15.82% | 16.95% | 17.43% | 17.01% | 16.51% |
| Non-institutions | 33.42% | 33.50% | 33.08% | 33.17% | 33.60% | 33.21% |
Jupiter Life Line Hospitals vs peers
The listed Pharma & Healthcare companies nearest to Jupiter Life Line Hospitals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| TITANBIOTitan Biotech | — | — | — | ₹1,793 Cr | — | — |
| FISCHERFischer Medical Ventures | ₹26.21 | +3.80% | −72.0% | ₹1,715 Cr | 58.2 | — |
| NGLFINENGL Fine-Chem | ₹2,717.20 | +3.00% | +80.2% | ₹1,679 Cr | 34.8 | — |
| KRSNAAKrsnaa Diagnostics | ₹510.75 | −0.79% | −38.5% | ₹1,657 Cr | 16.5 | — |
| JLHLJupiter Life Line Hospitals | ₹244.75 | −0.87% | −20.0% | ₹1,605 Cr | 8.3 | — |
| ASTECAstec LifeSciences | ₹700.20 | +6.41% | −5.5% | ₹1,560 Cr | — | — |
| SURAKSHASuraksha Diagnostic | ₹294.05 | +1.75% | +1.1% | ₹1,531 Cr | 47.6 | — |
Ask anything about Jupiter Life Line Hospitals
Pivot answers on the live chart with evidence you can check, and tests strategies against JLHL's own history. Try: “Why has JLHL moved over the last three months?” · “Backtest a 50-day moving-average crossover on JLHL over five years” · “Compare JLHL with TITANBIO on margins and valuation”
Frequently asked questions about Jupiter Life Line Hospitals
What is the share price of Jupiter Life Line Hospitals today?
Jupiter Life Line Hospitals (NSE: JLHL) last closed at ₹244.75 on 22 Oct 2026. Its 52-week high is ₹340.00 and its 52-week low is ₹234.95.
What is the market cap of Jupiter Life Line Hospitals?
Jupiter Life Line Hospitals' market capitalisation is ₹1,605 Cr (₹1,605 Cr) at the 22 Oct 2026 close, ranking 1230th among the NSE companies Pivot tracks.
What is the P/E ratio of Jupiter Life Line Hospitals?
Jupiter Life Line Hospitals trades at a trailing P/E of 8.3. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 47.6.
What is the ROE and ROCE of Jupiter Life Line Hospitals?
Return on equity was 12.6% in FY26 and return on capital employed was 13.8% in FY26 (consolidated figures).
Is Jupiter Life Line Hospitals a debt-free company?
No. Jupiter Life Line Hospitals' debt-to-equity ratio was 0.33 in FY26, with total debt of ₹501 Cr.
What were Jupiter Life Line Hospitals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Jupiter Life Line Hospitals reported revenue of ₹411 Cr, +18.2% year on year, and net profit of ₹38 Cr, −14.5% year on year.
How has Jupiter Life Line Hospitals stock performed over the last year?
Jupiter Life Line Hospitals' share price has fallen 20.0% over the past year, −21.8% over three months and −10.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Jupiter Life Line Hospitals?
As of 30 Jun 2026: promoters 40.91%, foreign institutions 9.37%, domestic institutions 16.51%, non-institutions 33.21%.
Who are Jupiter Life Line Hospitals' competitors?
The listed Pharma & Healthcare companies closest to Jupiter Life Line Hospitals by market cap are Titan Biotech, Fischer Medical Ventures, NGL Fine-Chem, Krsnaa Diagnostics, Astec LifeSciences and Suraksha Diagnostic.
Is Jupiter Life Line Hospitals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Jupiter Life Line Hospitals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JLHL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with J · all NSE stocks · this page as text